Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 4/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 6/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093763 | 0.87 | F10 (0.41) | F10MAOBECE1ABCB1PTGDR2 | |
| SCHEMBL829963 | 0.87 | F10 (0.41) | F10MAOBECE1ABCB1PTGDR2 | |
| SCHEMBL975576 | 0.81 | ECE1 (0.47) | F10MAOBECE1ABCB1PTGDR2 | |
| SCHEMBL832765 | 0.81 | ECE1 (0.44) | F10MAOBECE1PTGDR2CCR2 | |
| SCHEMBL1092733 | 0.80 | F10 (0.39) | F10ECE1ABCB1PTGDR2CCR2 | |
| SCHEMBL3150050 | 0.80 | PYGL (0.47) | F10MAOBECE1ABCB1PTGDR2 | |
| SCHEMBL831541 | 0.79 | CCR2 (0.40) | F10MAOBECE1ABCB1PTGDR2 | |
| SCHEMBL974067 | 0.77 | ECE1 (0.47) | F10MAOBECE1ABCB1PTGDR2 | |
| SCHEMBL1093308 | 0.76 | BCHE (0.37) | F10PTGDR2 | |
| SCHEMBL975637 | 0.76 | F10 (0.43) | F10MAOBECE1ABCB1PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420817-B2 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20120165531-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-28 | — | — | US | disclosed |
| US-8153796-B2 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | ZDHHC7, CNR2, HDAC3 | F10 2203/4885MAOB 59/4885ECE1 1971/4885 |
| US-20120165531-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | ZDHHC7, CNR2, HDAC3 | F10 2203/4885MAOB 59/4885ECE1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.